- Home
- ISPO vs NXTC Comparison
ISPO vs NXTC Comparison
Compare ISPO & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPO
- NXTC
- Stock Information
- Founded
- ISPO 2010
- NXTC 2015
- Country
- ISPO United States
- NXTC United States
- Employees
- ISPO N/A
- NXTC N/A
- Industry
- ISPO Blank Checks
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- ISPO Finance
- NXTC Health Care
- Exchange
- ISPO Nasdaq
- NXTC Nasdaq
- Market Cap
- ISPO 39.0M
- NXTC 40.3M
- IPO Year
- ISPO N/A
- NXTC 2019
- Fundamental
- Price
- ISPO $3.41
- NXTC $1.31
- Analyst Decision
- ISPO Buy
- NXTC Strong Buy
- Analyst Count
- ISPO 2
- NXTC 2
- Target Price
- ISPO $10.50
- NXTC $4.00
- AVG Volume (30 Days)
- ISPO 61.2K
- NXTC 44.0K
- Earning Date
- ISPO 10-28-2024
- NXTC 11-07-2024
- Dividend Yield
- ISPO N/A
- NXTC N/A
- EPS Growth
- ISPO N/A
- NXTC N/A
- EPS
- ISPO N/A
- NXTC N/A
- Revenue
- ISPO $287,451,000.00
- NXTC N/A
- Revenue This Year
- ISPO N/A
- NXTC N/A
- Revenue Next Year
- ISPO N/A
- NXTC N/A
- P/E Ratio
- ISPO N/A
- NXTC N/A
- Revenue Growth
- ISPO N/A
- NXTC N/A
- 52 Week Low
- ISPO $3.11
- NXTC $1.03
- 52 Week High
- ISPO $9.31
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- ISPO 40.13
- NXTC 45.61
- Support Level
- ISPO $3.27
- NXTC $1.30
- Resistance Level
- ISPO $3.64
- NXTC $1.60
- Average True Range (ATR)
- ISPO 0.28
- NXTC 0.08
- MACD
- ISPO -0.01
- NXTC 0.00
- Stochastic Oscillator
- ISPO 33.33
- NXTC 12.12
About ISPO Inspirato Incorporated
Inspirato Inc is a luxury travel subscription luxury travel company that provides exclusive access to a managed and controlled portfolio of curated vacation options, delivered through a model designed to ensure the service, certainty, and value that discerning customers demand. The Inspirato portfolio includes branded luxury vacation homes, accommodations at five-star hotel and resort partners, and custom travel experiences. It has a geographic location in the United States and Outside the United States. It generates the majority of its revenue from the United States.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.